EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

High doses of rosuvastatin induce impaired branched‐chain amino acid catabolism and lead to insulin resistance

Xue Bai iD, Xingzhen Long, Fang Song, Baolin Chen, Changcheng Sheng, Cailin Tang, Li Li, Jiaxing Zhang, Rui Zhang, Jiquan Zhang, Jiali Li

Experimental Physiology · 2023

DOI: 10.1113/ep090305 ↗

At a glance

Journal article in Experimental Physiology, 2023. Written by Xue Bai and 10 co-authors. Institution: Department of Pharmacy, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China. Major MEDLINE topics: Diabetes Mellitus, Insulin Resistance. Cited 7 times so far (Crossref); 56 references. The full text is freely available (open access, CC BY 4.0). Funded by: Science and Technology Support Program of Guizhou Province, Youth Fund of Guizhou Provincial People's Hospital, Science and Technology Fund Project of Health and Planning Commission of Guizhou Province.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Accumulating evidence indicates that patients treated with rosuvastatin have an increased risk of developing new‐onset diabetes. However, the underlying mechanism remains unclear. In this study, we administered rosuvastatin (10 mg/kg body weight) to male C57BL/6J mice for 12 weeks and found that oral rosuvastatin dramatically reduced intraperitoneal glucose tolerance. Rosuvastatin‐treated mice showed considerably higher serum levels of branched‐chain amino acids (BCAAs) than control mice. They also showed dramatically altered expression of BCAA catabolism‐related enzymes in white adipose tissue and skeletal muscle, including downregulated mRNA expression of BCAT2 and protein phosphatase 2Cm ( PP2Cm ) and upregulated mRNA expression of branched‐chain ketoacid dehydrogenase kinase ( BCKDK ). The levels of BCKD in the skeletal muscle were reduced in rosuvastatin‐treated mice, which was associated with lower PP2Cm protein levels and increased BCKDK levels. We also investigated the effects of rosuvastatin and insulin administration on glucose metabolism and BCAA catabolism in C2C12 myoblasts. We observed that incubation with insulin enhanced glucose uptake and facilitated BCAA catabolism in C2C12 cells, which was accompanied by elevated Akt and glycogen synthase kinase 3 β (GSK3β) phosphorylation. These effects of insulin were prevented by co‐incubation of the cells with 25 μM rosuvastatin. Moreover, the effects of insulin and rosuvastatin administration on glucose uptake and Akt and GSK3β signaling in C2C12 cells were abolished when PP2Cm was knocked down. Although the relevance of these data, obtained with high doses of rosuvastatin in mice, to therapeutic doses in humans remains to be elucidated, this study highlights a potential mechanism for the diabetogenic effects of rosuvastatin, and suggests that BCAA catabolism could be a pharmacological target for preventing the adverse effects of rosuvastatin.

Subjects

MeSH terms (MEDLINE)

Diabetes MellitusInsulin ResistanceAnimalsMaleMiceAmino Acids, Branched-ChainGlucoseGlycogen Synthase Kinase 3 betaInsulinMice, Inbred C57BLPhosphoprotein PhosphatasesProto-Oncogene Proteins c-aktRNA, MessengerRosuvastatin Calcium

Author keywords

AktBCAA catabolismGSK3βPP2Cminsulin resistancerosuvastatin

Substances

Amino Acids, Branched-ChainGlucoseGlycogen Synthase Kinase 3 betaInsulinPhosphoprotein PhosphatasesProto-Oncogene Proteins c-aktRNA, MessengerRosuvastatin Calcium

Authors and institutions

  • Department of Pharmacy, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China.
  • The First Affiliated Hospital, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China.
  • Department of Cardiology, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China.
  • State Key Laboratory of Functions and Applications of Medicinal Plants & College of Pharmacy, Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, Guizhou…
  • Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, Guangdong, China.

ORCID profiles: Xue Bai

Funding

  • Science and Technology Support Program of Guizhou Province
  • Youth Fund of Guizhou Provincial People's Hospital
  • Science and Technology Fund Project of Health and Planning Commission of Guizhou Province

Cite

APA

Bai, X., Long, X., Song, F., Chen, B., Sheng, C., Tang, C., Li, L., Zhang, J., Zhang, R., Zhang, J., & Li, J. (2023). High doses of rosuvastatin induce impaired branched‐chain amino acid catabolism and lead to insulin resistance. Experimental Physiology. https://doi.org/10.1113/ep090305

Vancouver

Bai X, Long X, Song F, Chen B, Sheng C, Tang C, et al. High doses of rosuvastatin induce impaired branched‐chain amino acid catabolism and lead to insulin resistance. Experimental Physiology. 2023. doi:10.1113/ep090305

BibTeX
@article{Bai2023,
  author = {Bai, Xue and Long, Xingzhen and Song, Fang and Chen, Baolin and Sheng, Changcheng and Tang, Cailin and Li, Li and Zhang, Jiaxing and Zhang, Rui and Zhang, Jiquan and Li, Jiali},
  title = {High doses of rosuvastatin induce impaired branched‐chain amino acid catabolism and lead to insulin resistance},
  journal = {Experimental Physiology},
  year = {2023},
  doi = {10.1113/ep090305}
}
Start for free →